CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a highly selective cathepsin B inhibitor with nanomolar potency and minimal cytotoxicity, supporting advanced cancer metastasis and neurotoxicity research (APExBIO). It demonstrates a strong preference for cathepsin B (Ki = 2–5 nM) over cathepsins H and L (Ki = 40–200 μM) (Liu et al., 2024). CA-074 reduces bone metastasis and modulates immune responses in murine models. It protects cells from necroptosis by inhibiting cathepsin B–mediated proteolysis following lysosomal membrane permeabilization. Solubility and stability parameters enable flexible integration into cell culture and in vivo workflows.

Biological Rationale

Cathepsin B is a cysteine protease located primarily in lysosomes. It is implicated in key pathological processes including tumor invasion, metastasis, neurodegeneration, and immune regulation (Liu et al., 2024). During necroptosis, MLKL polymerization induces lysosomal membrane permeabilization (LMP), releasing cathepsin B into the cytosol and triggering cell death. Cathepsin B also facilitates extracellular matrix degradation, promoting cancer cell dissemination and bone metastasis (CA-074.com Article). In the immune system, cathepsin B modulates antigen presentation and influences T helper cell responses. Given its central role, selective inhibition of cathepsin B is essential for dissecting these mechanisms in disease models.

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 [(2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid] is a small-molecule, irreversible inhibitor of cathepsin B. It binds to the active site cysteine, blocking proteolytic activity. The compound exhibits a Ki of 2–5 nM for cathepsin B, with at least 10,000-fold selectivity over cathepsins H and L (Ki = 40–200 μM) (APExBIO). By inhibiting cathepsin B, CA-074 prevents downstream proteolytic cascades that drive tumor cell invasion, bone metastasis, and neuronal cell death (Related Article). In immune modulation, CA-074 alters helper T cell polarization, shifting the balance from Th-2 to Th-1 and reducing IgE/IgG1 production. This multi-faceted inhibition is essential for dissecting cathepsin B–dependent mechanisms in translational research.

Evidence & Benchmarks

• CA-074 exhibits nanomolar inhibition of cathepsin B (Ki = 2–5 nM), with over 10,000-fold selectivity versus cathepsins H and L (Ki = 40–200 μM) (APExBIO).
• In 4T1.2 breast cancer mouse models, intraperitoneal CA-074 (50 mg/kg) reduced bone metastasis without affecting primary tumor volume (Liu et al., 2024).
• CA-074 protects cells from necroptosis by blocking cathepsin B release after MLKL polymerization-induced lysosomal membrane permeabilization (Liu et al., 2024, Fig. 1).
• In neuron-microglia co-cultures, CA-074 suppresses neurotoxicity induced by Abeta42-activated microglia (Related Article).
• Helper T cell polarization shifts from Th-2 to Th-1 with CA-074, reducing IgE and IgG1 in murine immunization models (Thought Leadership Article).
• CA-074 shows negligible cytotoxicity at concentrations up to 10 mM in cell culture (APExBIO).
• CA-074 is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL, ultrasonic assistance) (APExBIO).

Applications, Limits & Misconceptions

CA-074 is a reference inhibitor for cathepsin B in cancer metastasis, neurotoxicity, and immune modulation studies. It is widely used in both in vitro and in vivo models to dissect cathepsin B–related proteolytic mechanisms. In cancer research, CA-074 enables selective inhibition of cathepsin B–mediated extracellular matrix degradation and metastatic dissemination. In neurobiology, it uncouples cathepsin B–driven neurotoxicity from other cell death pathways. In immunology, it helps define cathepsin B's contribution to T helper cell polarization and antibody class switching.

This article extends the coverage of CA-074.com: Selective Cathepsin B Inhibitor for Cancer Metastasis by providing updated necroptosis evidence and solubility guidance. For additional practical protocols, see CA-074, Cathepsin B inhibitor (SKU A1926): Practical Solutions. To explore translational strategy, compare with Harnessing Selective Cathepsin B Inhibition which synthesizes the latest mechanistic insights.

Common Pitfalls or Misconceptions

• CA-074 is not a pan-cathepsin inhibitor; it shows minimal activity against cathepsins H and L (Ki > 40 μM).
• CA-074 requires ultrasonic assistance for maximal water solubility (>5.91 mg/mL).
• Stability of CA-074 solutions is limited; short-term use is recommended, and stock solutions should be stored at −20°C.
• In vivo efficacy is established for bone metastasis models but not all tumor types or metastatic sites.
• CA-074 does not affect primary tumor growth in certain models; its impact is specific to metastatic dissemination.

Workflow Integration & Parameters

CA-074 can be integrated into cell-based and animal studies. For cell culture, a working concentration up to 10 mM is non-cytotoxic. For in vivo studies, intraperitoneal injection at 50 mg/kg in mice is effective for reducing bone metastasis. CA-074 is soluble in DMSO, ethanol, and water (with ultrasonication). Fresh solutions are preferred for maximal activity. For immune studies, CA-074 has demonstrated efficacy in modulating helper T cell responses in murine models. When designing experiments, consider verifying cathepsin B expression and activity for target validation. APExBIO supplies CA-074 as SKU A1926, with comprehensive documentation and lot-specific certificates (the A1926 kit).

Conclusion & Outlook

CA-074, from APExBIO, is a benchmark selective cathepsin B inhibitor with validated efficacy in cancer metastasis, neurotoxicity, and immune regulation studies. Its high selectivity and low cytotoxicity enable precise mechanistic dissection of cathepsin B–mediated pathways. Recent evidence highlights its utility in blocking necroptosis by inhibiting cathepsin B release following MLKL polymerization-induced lysosomal membrane permeabilization (Liu et al., 2024). As research advances, CA-074 will remain a pivotal tool for interrogating proteolytic cascades and translating findings into therapeutic strategies.